Business Wire

Pattern Computer Develops Accurate 15-Second COVID-19 Test

Share

Pattern Computer,® Inc. (PCI) has developed a novel test for near real-time (15 sec) diagnosis of SARS-CoV-2 infections. In contrast with widely used antibody and PCR tests, which take at least 15 minutes to produce results, and require scarce reagents to process, the newly developed PCI method enables high-volume throughput of tests without requiring chemical reagents at difficult to service locations, such as company entrances, event venues, court houses, state and federal facilities, TSA screening areas and ports of entry.

“Having a simple, fast, easy to administer, high accuracy COVID-19 test will be critical for TSA and the airline carriers to increase passenger safety and confidence, as carriers deal with rising passenger loads and increased health security requirements,” said Bob Edwards, former CIO for United Airlines. “Pattern Computer’s new system appears to meet that need.”

Developed using the Pattern Discovery Engine™ (PDE) comprised of proprietary software methods and specially configured hardware, the initial results suggest this low-cost, high-volume COVID-19 test could create new opportunities for reducing transmission risk in high-headcount, high-density entertainment venues, large-scale events, office buildings, trains, busses, aircraft, and subways.

“As the world enters the next cycles of COVID lockdowns and flareups, there will be a pressing need for the companion technology to vaccines – the ability to detect true positive infections, and simultaneously reduce the incidence of false positives, coupled with higher reliability rates, delivered in real time. These are the required characteristics of a regimen of testing that will enable better containment of future outbreaks. The Pattern Computer team was able to apply the proven abilities of the Pattern Discovery Engine to take on this daunting challenge. We wanted to create a high-performance, extremely accurate, reagent-free, real-time alternative for testing in the world’s most important venues. This combination of proprietary hardware and software appears capable of meeting that critical need,” according to Mark R. Anderson, CEO of Pattern Computer.

Pattern Computer’s new test has been used to analyze data from symptomatic and asymptomatic patients between 10 and 80 years old. The reported balanced accuracy of the new test is >96%. The aspects of the testing that are worth noting: the Pattern team has been working on the problem for a few months, and is working with a dataset that numbers in the hundreds of data points. Competing organizations and teams have been working on the same problem for over a year with millions of data points, to only deliver tests that are 97% accurate.

The results from the Pattern tests are competitive with the performance of antibody tests currently in the market, which under ideal conditions (3 weeks after onset of symptoms) reports a balanced accuracy of 95%1. In contrast to antibody tests, which are highly sensitive to timing--only 30% of people infected with SARS-CoV-2 tests positive 1 week after the onset of symptoms--the performance of PCI diagnosis is agnostic regarding how long the patient has been symptomatic.

“Pattern Computer has rapidly developed a reagent free SARS-CoV-2 diagnostic platform with an impressive level of accuracy. This technology has the potential to alter the landscape of disease diagnostics. Currently, they are focused on COVID-19, but their approach is applicable, in principle, to any disease. I suspect that, in the new future, as we walk through TSA security at an airport, part of the screen will be for infectious diseases. The implications of this technology for public safety and health, especially disease surveillance, are enormous,” said Prof. J. Ben Brown, UC Berkeley & Lawrence Berkeley National Laboratory.

PCI has built an initial model that predicts COVID-19 status (as determined by multi-target RT-PCR) of a patient based on its proprietary hardware measurements. Sensitivity and specificity are computed with 5-fold cross-validation.

PCI expects that as more data points are added to the PCI data base, particularly data from non-infected individuals, its technology will be able to match or exceed RT-PCR for accurate SARS-CoV-2 infection detection, with the reduced result time of 20 seconds rather than the current standard wait time of 30 minutes or more2.

The foregoing contains statements about the Pattern Computer’s future that are not statements of historical fact. These statements are “forward-looking statements” for purposes of applicable securities laws and are based on current information and/or management's good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.

About Pattern Computer

Pattern Computer, Inc., a Seattle-area startup, uses its proprietary Pattern Discovery Engine to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems.

While the company is currently applying its computational platform to the challenging field of drug discovery, it is also making pattern discoveries for partners in several other sectors, including additional biomedical research, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance.

For more information on Pattern Computer Inc., visit: www.patterncomputer.com

For more information about Mark Anderson, visit: www.patterncomputer.com/founders/

Copyright © 2021 Pattern Computer, Inc. All Rights Reserved. Pattern Computer Inc., and PCI are trademarks of Pattern Computer, Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.

_________________________________________________

1 Antibody tests for identification of current and past infection with SARS‐CoV‐2 - Deeks, JJ - 2020 | Cochrane Library, https://doi.org/10.1002/14651858.CD013652 , June 25, 2020
2 Covid-19: Bosch develops “fastest” PCR test in the world (msn.com), https://www.msn.com/en-ae/news/other/covid-19-bosch-develops-fastest-pcr-test-in-the-world/ar-BB1aNLVB, August 11, 2020

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Denyse Hudson
360.298.0658
denyse@patterncomputer.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kyowa Kirin Provides Update on Application for Marketing Authorisation of Istradefylline in Europe for the Treatment of ‘OFF’ Episodes in People Living with Parkinson’s23.7.2021 17:05:00 EEST | Press release

Kyowa Kirin Co., Ltd. (TSE:4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for istradefylline as an add-on treatment to levodopa (L-Dopa) based regimens in adults living with Parkinson’s, experiencing end-of-dose motor fluctuations. Kyowa Kirin International remain committed to istradefylline and people living with Parkinson’s and are currently reviewing the options available, which may include re-examination. “We are disappointed by the CHMP opinion. However, we remain confident in the benefit-risk profile of istradefylline and are committed to making a difference to the lives of people living with Parkinson’s, an area which has had few innovative therapies for decades,” said Abdul Mullick, President of Kyowa Kirin International. “There are currently few new treatment options available to manage end-of-dose motor fluctuations in Parkinson

ForumPay Teams Up with Bambora to Conquer the Crypto-to-Fiat Payments Market23.7.2021 16:16:00 EEST | Press release

ForumPay, an international cryptocurrency-to-fiat payment service provider, has established a partnership with the global payments provider Bambora, a Worldline brand, to bring seamless crypto payment solutions to merchants and online shoppers. The partnership will cater to a large global audience and offer expanded payment options for both shoppers and merchants. ForumPay continues its march to dominate the growing crypto payments ecosystem for merchants around the world. “ForumPay provides merchants with a seamless, secure and instant processing solution to accept payments from the more than 54 million active crypto wallet users around the world. By providing a payments service for processing crypto into fiat that functions as naturally as card payments, ForumPay enables merchants with a familiar feeling payments alternative that also gives them a competitive advantage by tapping into the fastest growing consumer base on the planet.” says Joshua Tate, CEO of ForumPay. “We are very ex

Wipro Recognized as 2021 Microsoft Modernizing Applications Partner of the Year23.7.2021 15:54:00 EEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has won the 2021 Microsoft Partner of the Year Award in the Modernizing Applications category. In addition, Wipro was also named as a category finalist in the 2021 AI Partner of the Year category, solidifying its reputation as an innovator in multiple sectors. This recognition highlights Wipro’s deep expertise and ability to go above and beyond for its customers, powered by an established partnership with Microsoft. Even when working with complex customer environments, spanning across hundreds of servers with different applications of different versions, Wipro was able to help customers meet their business needs and leverage the power of public cloud in an efficient way. “Global enterprises have embraced modernization at an unprecedented scale and pace, and the demands of the past year show no sign of easing. We are honor

Merck Announces Appointment of Head of China & International for Healthcare23.7.2021 14:45:00 EEST | Press release

Merck, a leading science and technology company, today announced that Hong Chow will join its Healthcare business sector as Head of China & International on October 1. In this role at Merck, Chow will lead China, Japan as well the regions Europe, Latin America, Asia-Pacific and Middle East, Africa and Russia, the franchise of Cardiovascular Metabolism & Endocrinology (CM&E), and the Global Business Innovation team. Chow will report to Peter Guenter, Member of the Executive Board of Merck and CEO Healthcare. She will serve as a member of the Healthcare Executive Committee, and be based in Shanghai, China. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210723005186/en/ Merck Announces Appointment of Head of China & International for Healthcare (Photo: Business Wire) “Hong’s international experience and strong track record of bringing innovative medicines to patients in need across both developed and emerging markets, most nota

H.I.G. WhiteHorse Refinances Grupo Recoletas23.7.2021 14:03:00 EEST | Press release

H.I.G. WhiteHorse, a credit affiliate of global investment firm H.I.G. Capital ("H.I.G.") is pleased to announce that it has arranged a refinancing package for Grupo Hospitalario Recoletas (“Recoletas”), which includes a significant growth capital component. Recoletas is a family-owned Spanish private hospital operator headquartered in Valladolid, Spain, with a leading position in the Castilla y Leon Spanish inland region. It operates 8 hospitals with c. 540 beds and 13 medical centres across 7 regions. H.I.G. WhiteHorse has committed €110 million in unitranche loans to refinance the borrower's existing indebtedness and provide additional capital to finance growth, supporting the Company’s expansion. Recoletas is currently developing ambitious projects to expand its healthcare services provided through hospitals and medical centers, as well as diagnostic imaging centers and radiotherapy units. Amando J. Rodríguez, President and CEO of Grupo Hospitalario Recoletas, said: “We are very ha

Schlumberger Announces Second-Quarter 2021 Results23.7.2021 13:50:00 EEST | Press release

Schlumberger Limited (NYSE: SLB) today reported results for the second-quarter 2021. Second-Quarter Results (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2021 Mar. 31, 2021 Jun. 30, 2020 Sequential Year-on-year Revenue* $5,634 $5,223 $5,356 8% 5% Income (loss) before taxes - GAAP basis $542 $386 $(3,627) 40% n/m Net income (loss) - GAAP basis $431 $299 $(3,434) 44% n/m Diluted EPS (loss per share) - GAAP basis $0.30 $0.21 $(2.47) 43% n/m Adjusted EBITDA** $1,198 $1,049 $838 14% 43% Adjusted EBITDA margin** 21.3% 20.1% 15.6% 118 bps 561 bps Pretax segment operating income** $807 $664 $396 22% 104% Pretax segment operating margin** 14.3% 12.7% 7.4% 162 bps 694 bps Net income, excluding charges & credits** $431 $299 $69 44% 525% Diluted EPS, excluding charges & credits** $0.30 $0.21 $0.05 43% 500% Revenue by Geography International $4,511 $4,211 $4,224 7% 7% North America* 1,083 972 1,097 11% -1% Other 40 40 35 n/m n/m $5,634 $5,223 $5,356 8% 5% *Schlum

Wyss Center Partners With Artiria Medical to Accelerate a Novel Therapy for Cerebral Vasospasm23.7.2021 12:59:00 EEST | Press release

The Wyss Center and Artiria Medical today announced a new partnership to accelerate the translation of a novel technology that has the potential to reduce deaths and improve quality of life for stroke patients. Artiria Medical, an early-stage medical device company focused on disruptive neurovascular products, has been developing the technology and is now joining forces with the Wyss Center, a non-profit organization dedicated to bringing state-of-the-art therapies to the patient. The team has received support from the Swiss Innovation Agency, Innosuisse, to test and validate the efficacy of the therapy preclinically, in preparation for human clinical studies. Stroke is the third leading cause of disability worldwide with more than 80 million people living with long-term impairments as a result. Some strokes result in bleeding in the brain. Such hemorrhagic strokes can lead to severe cerebral vasospasm - an uncontrolled contraction of brain arteries - in the days that follow, depriving

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom